1966
DOI: 10.1097/00007890-196607000-00002
|View full text |Cite
|
Sign up to set email alerts
|

Experimental Renal Heterotransplantation

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1
1

Citation Types

3
42
0
6

Year Published

1969
1969
2003
2003

Publication Types

Select...
9
1

Relationship

0
10

Authors

Journals

citations
Cited by 154 publications
(51 citation statements)
references
References 0 publications
3
42
0
6
Order By: Relevance
“…2) and deposition of those antibodies in the graft (Fig. 3 A , top ), a result consistent with previous studies (3,19,40). Anti-Gal ␣ 1-3Gal IgM in particular was undetectable in the blood of recipients after transplantation, confirming the idea that anti-Gal ␣ 1-3Gal IgM is a major specificity of antibodies adsorbed by pig-to-primate xenografts, and is involved in the pathogenesis of hyperacute xenograft rejection (41).…”
Section: Development Of Acute Vascular Rejection In Baboonssupporting
confidence: 90%
“…2) and deposition of those antibodies in the graft (Fig. 3 A , top ), a result consistent with previous studies (3,19,40). Anti-Gal ␣ 1-3Gal IgM in particular was undetectable in the blood of recipients after transplantation, confirming the idea that anti-Gal ␣ 1-3Gal IgM is a major specificity of antibodies adsorbed by pig-to-primate xenografts, and is involved in the pathogenesis of hyperacute xenograft rejection (41).…”
Section: Development Of Acute Vascular Rejection In Baboonssupporting
confidence: 90%
“…4B). The hearts had histopathologic findings of rejection similar to those reported previously (14), DISCUSSION The therapeutic implication of inhibiting or depleting complement has been a recurring theme of transplantation research since the HAR syndromes were recognized in allograft recipients who had preformed antigraft antibodies (15)(16)(17), the same events were described in discordant xenotransplant models (18), and Gewurz et a1. (19) demonstrated that the HAR of organ allografts and xenografts was a complement activation syndrome.…”
Section: ~------------------------supporting
confidence: 67%
“…Xenoreactive immunity is very vigorous; hence, a profound form of immunosuppression and/or immunomanipulation will be needed to prevent rejection of xenografts. The first form of xenorejection, hyperacute rejection, occurs upon reperfusion of xenografts by the recipient blood because of binding of natural xenoantibodies to endothelial cells of the graft and activation of the complement system (1,2). This can be overcome by interfering with the complement system, e.g., by using genetically modified donors (3).…”
Section: Pathogenesis Of Autoimmunity After Xenogeneic Thymus Transplmentioning
confidence: 99%